DNA倍体及MDR1与宫颈癌新辅助化疗耐药相关性分析

发布时间：2019-02-13 02:14

【摘要】：目的针对DNA倍体及MDR1与宫颈癌新辅助化疗耐药相关性进行研究和分析。方法选取2015年1月—2017年1月,到我院进行治疗的48例LACC患者。对所有患者采取HBP方案化疗,并进行DNA定量分析检测。评价患者化疗后的疗效以及染色结果。结果经过新辅助化疗治疗,有效患者(完全缓解及部分缓解)27例(56.25%),其DNA倍体异倍表达率(3.7%)明显低于无效患者(38.10%)(P0.05),且MDR1表达量(1.09±0.47)低于无效患者(2.80±0.69),差异显著,有统计学意义(P0.05)。结论 DNA倍体及MDR1与宫颈癌新辅助化疗耐药性有关,耐药性较高的患者,DNA倍体异倍表达率更高,且MDR1表达量更大,可以作为临床上选择宫颈癌新辅助化疗治疗方案的重要参考。
[Abstract]:Objective to study and analyze the correlation between DNA ploidy, MDR1 and neoadjuvant chemotherapeutic resistance in cervical cancer. Methods from January 2015 to January 2017, 48 patients with LACC were treated in our hospital. All patients were treated with HBP regimen chemotherapy, and DNA quantitative analysis was performed. To evaluate the curative effect and staining results after chemotherapy. Results after neoadjuvant chemotherapy, 27 cases (56.25%) were effective (complete remission and partial remission), and the rate of DNA ploidy aneuploidy (3.7%) was significantly lower than that in ineffective patients (38.10%) (P0.05). The expression of MDR1 (1.09 卤0.47) was significantly lower than that of ineffective patients (2.80 卤0.69) (P0.05). Conclusion DNA ploidy and MDR1 are related to neoadjuvant chemotherapeutic resistance of cervical cancer. The DNA ploidy expression rate is higher and the MDR1 expression is larger in the patients with higher chemotherapeutic resistance. It can be used as an important reference for clinical selection of neoadjuvant chemotherapy regimen for cervical cancer.
【作者单位】：深圳市人民医院妇科;
【分类号】：R737.33

【相似文献】